Envestnet Portfolio Solutions Inc. Lowers Stock Position in Haleon plc (NYSE:HLN)

Envestnet Portfolio Solutions Inc. reduced its position in Haleon plc (NYSE:HLN) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 179,896 shares of the company’s stock after selling 4,629 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Haleon were worth $1,716,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in HLN. Sierra Ocean LLC acquired a new position in Haleon during the fourth quarter valued at approximately $26,000. Versant Capital Management Inc lifted its holdings in shares of Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Haleon during the 4th quarter worth $35,000. Toronto Dominion Bank raised its position in Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares during the period. Finally, Spire Wealth Management acquired a new position in shares of Haleon during the fourth quarter worth about $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 1.0 %

Shares of Haleon stock opened at $10.29 on Friday. The firm has a market cap of $46.56 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.82 and a beta of 0.25. The business has a 50-day moving average price of $9.84 and a 200 day moving average price of $9.88. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.99 and a fifty-two week high of $10.80.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. On average, sell-side analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is 58.97%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Finally, Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Haleon currently has an average rating of “Hold” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.